Deutsche Bank Appointed as Successor Depositary Bank for the NYSE-Listed American Depositary Receipt Program of AstraZeneca PLC
Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt Program of AstraZeneca PLC (NYSE: AZN). AstraZeneca is a global, science-led biopharmaceutical company focusing on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in the therapy areas of Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in more than 100 countries.*. "We are pleased to have been appointed as successor depositary bank for the AstraZeneca PLC American Depositary Receipt program, which is one of the largest and most liquid in the world," said Daniel Clark, Global Head of Depositary Receipts at Deutsche Bank. In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. Deutsche Bank offers a very broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.
Story Sourcesfinance.yahoo.com businesswire.com business.financialpost.com business.itbusinessnet.com